Healthcare professionals should prescribe pre-exposure prophylaxis (PrEP) to people at increased risk for HIV.
The U.S. Preventive Services Task Force (Task Force) [on August 22] published a final recommendation statement on pre-exposure prophylaxis (PrEP) for the prevention of HIV. Based on its review of the evidence, the Task Force recommends that healthcare professionals prescribe PrEP to people at increased risk for HIV to help prevent HIV. This is an A grade.
So, What's New with this Recommendation?
The USPSTF issued an essentially similar recommendation in 2019. USPSTF's writes, in Update of Previous USPSTF Recommendation: "For the current recommendation, the USPSTF reviewed additional evidence on new formulations of PrEP and recommends that clinicians prescribe PrEP using effective antiretroviral therapy to persons at increased risk of HIV acquisition, after the clinician and patient have discussed PrEP and the patient agrees."
Furthermore, the Clinician Summary, under What’s new?, reads:
- This recommendation is consistent with the 2019 USPSTF recommendation on PrEP for the prevention of HIV.
- For the current recommendation, the USPSTF reviewed additional evidence on new formulations of PrEP (tenofovir alafenamide/emtricitabine [TAF/FTC] and cabotegravir).